Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ropivacaine hydrochloride -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 105.4 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - bupivacaine injection is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery - field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in post operative pain or labour pain. - field block (minor nerve block amd infiltration). the choice of 2 strengths, 0.25% and 0.5%, makes it possible to vary the degree of motor blockade.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cytarabine, quantity: 1 g - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. may be used alone or in combination with other antineoplastic agents, the best results often being obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa 2l2) that includes cytarabine. indications as at 24 october 2001: cytarabine is indicated primarily for: induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combined therapy. children with

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisplatin, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; mannitol; hydrochloric acid; water for injections; sodium hydroxide - cisplatin injection may be used singularly or in combination with other chemotherapeutic agents in the treatment of: - metastatic nonseminomatous germ cell carcinoma; advanced stage, refractory ovarian carcinoma; advanced stage, refractory bladder carcinoma; refractory squamous cell carcinoma of the head and neck

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer consumer healthcare ltd - ibuprofen - oral capsule - 400mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer consumer healthcare ltd - ibuprofen - oral capsule - 200mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - exemestane -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - amlodipine -